UPB Key Statistics, Chart & Performance
The current stock price of UPB is 28.53 USD. In the past month the price increased by 16.06%. In the past year, price increased by 31.82%.
UPB Latest News, Press Relases and Analysis
UPB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.07 | 401.89B | ||
| AMGN | AMGEN INC | 15.76 | 185.57B | ||
| GILD | GILEAD SCIENCES INC | 15.61 | 158.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 110.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.48 | 83.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 871.84 | 58.28B | ||
| INSM | INSMED INC | N/A | 43.42B | ||
| NTRA | NATERA INC | N/A | 32.64B | ||
| BIIB | BIOGEN INC | 10.91 | 26.77B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.58 | 22.18B | ||
| INCY | INCYTE CORP | 16.57 | 20.77B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About UPB
Company Profile
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The company has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
Company Info
UPSTREAM BIO INC
890 Winter Street, Suite 200
Waltham MASSACHUSETTS US
Employees: 52
Phone: 17812082466
UPSTREAM BIO INC / UPB FAQ
What does UPB do?
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The company has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
Can you provide the latest stock price for UPSTREAM BIO INC?
The current stock price of UPB is 28.53 USD. The price decreased by -1.04% in the last trading session.
Does UPB stock pay dividends?
UPB does not pay a dividend.
What is the ChartMill technical and fundamental rating of UPB stock?
UPB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is UPB stock listed?
UPB stock is listed on the Nasdaq exchange.
What is the next earnings date for UPB stock?
UPSTREAM BIO INC (UPB) will report earnings on 2026-03-10.
Can you provide the short interest for UPB stock?
The outstanding short interest for UPSTREAM BIO INC (UPB) is 7.28% of its float.
UPB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to UPB. When comparing the yearly performance of all stocks, UPB is one of the better performing stocks in the market, outperforming 93.81% of all stocks.
UPB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UPB. UPB has a great financial health rating, but its profitability evaluates not so good.
UPB Financial Highlights
Over the last trailing twelve months UPB reported a non-GAAP Earnings per Share(EPS) of -3.47. The EPS decreased by -99.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.38% | ||
| ROE | -32.43% | ||
| Debt/Equity | 0 |
UPB Forecast & Estimates
9 analysts have analysed UPB and the average price target is 62.22 USD. This implies a price increase of 118.09% is expected in the next year compared to the current price of 28.53.
For the next year, analysts expect an EPS growth of 64.81% and a revenue growth 10.82% for UPB